I studied Biochemistry in Melbourne at La Trobe University where I completed my bachelors with honours, and undertook a PhD in drug discovery and inflammation. La Trobe has an exceptional biochemistry program, and I was thrilled to be accepted and be part of it. I then made the leap across to London for four years to continue my research at the Institute of Cancer Research, where I got to be part of a fantastic lab and where I learnt many critical skills. I then accepted a position as Laboratory Head at WEHI in 2020 and I now lead a team of 10 incredible scientists, 4 post-doctoral researchers, 5 PhD students and 1 RA to target ‘undruggable’ inflammatory proteins.
My team is highly motivated, has a fierce intellect and collaborate extensively nationally and internationally to achieve our scientific goals.
Our most recent achievement has been the introduction of an innovative drug discovery technology to WEHI and we are the leaders behind the development, integration and uptake of this technology amongst the larger biosciences sector across Australia.
Australia, La Trobe University, BSc (Hons), 2007
Australia, La Trobe University, PhD, 2010
2023* $100,000 to kickstart degron technology projects, WEHI Theme funds
2022* $50,000 Philanthropy donation Betty Deller King bequest gift
2022* $25,350 Philanthropy donation K & M Foundation for Women
2021 $1M Medical Research Future Fund (split over three labs)
2020 – 2022* $300,154 Chief investigator (CIB) Cancer Council Victoria grant APP1185830
2020* $500,000 Philanthropy donation Galbraith Family Charitable trust
2019* $360,000 WEHI lab head startup package, p.a for 7 years
2019* $500,000 Philanthropy donation to fund dTAG PROTAC technology initiatives
2015 $633, 813 NHMRC New Investigator Funding. 3 years. GNT1081272
The projects undertaken in my lab are some of the most exciting in the ubiquitin field.
We utilise diverse techniques from basic biochemistry, for example cloning and western blotting, to complex cellular and in vivo systems, for example CRISPR/Cas9 targeting and laboratory models of disease.
Specifically, we focus our efforts on identifying, characterising and targeting E3 ubiquitin ligases using two main approaches:
1. Cell-based screens to identify critical E3 ligases that regulate inflammatory signalling.
2. PROTAC-based targeting strategies (dTAG) to validate E3 ligases as therapeutic targets.
Ultimately this work will help in our understanding of how ubiquitin signalling is deregulated in cancer and chronic inflammatory disease to aid in the development of new therapies